Therapy for Scabies With Two Differently Concentrated Permethrin Creams

Inclusion Criteria: * Confirmed acute scabies disease: Detection of mites and/or mite nymphs and/or mite larvae, by reflected light microscopy or light microscopy of skin samples, at scabies-typical predilection sites * Age between 2 years and 85 years * Written informed consent of the study participant (if of legal age) or all legal guardians (for underage study participants \< 12 years) or all legal guardians and the study participant (for underage study participants ≥ 12 years) * Practicable application of the trial medication by trained specialist staff at the trial site Exclusion Criteria: * Pre-treatment with antiscabiosa in the last 14 days * Combined antiscabial treatment (i.e. simultaneous/simultaneous topical and systemic scabies treatment with medication) in the last 3 months * Known intolerance to permethrin, other pyrethroids, chrysanthemums or any of the other ingredients of the study medication * Scabies crustosa * Impetiginization/eczematization requiring inpatient treatment * Body weight \> 120 kg * Pregnancy, breastfeeding * Clinically relevant immunodeficiency (of any kind, including extensive local therapy (\>20% body surface) with corticosteroids \> 2 weeks in the last 4 weeks or ≥ 10 mg prednisolone equivalent \>7 days in the last 4 weeks - even without signs of scabies crustosa) * Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study * Planned systemic use of corticosteroids * Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants * Apparent unreliability or unwillingness to cooperate * Inability to understand and comply with study instructions * Known alcohol, medication or drug dependence * Placement in a facility where people live together for long periods of time, are cared for or receive medical care, and where close skin-to-skin contact is common, or placement in an institution ordered by a court/authority * 5 or more close contacts (persons with close, extensive skin-to-skin contact with the scabies patient for more than 5-10 minutes) * Close contact person who refuses scabies treatment or for whom treatment is not possible * Dependence on sponsor or investigator * Previous participation in a clinical trial in the last 30 days or in the same clinical trial